Spread the love

A new drug cocktail is four times more effective at keeping Covid patients out of intensive care, initial tests have suggested.

While the steroid dexamethasone was the first drug to be licensed for treating the virus, trials indicate that combining it with heart failure medication spironolactone yields better results.

A study, conducted by former vice-chancellor of Newcastle University Sir Christopher Edwards, analysed hospital patients in Delhi.

In hospitalised patients taking the ‘Spidex’ cocktail, just 5.4 per cent were admitted to intensive care compared to 19.6 per cent of just dexamethasone

In hospitalised patients taking the ‘Spidex’ cocktail, just 5.4 per cent were admitted to intensive care compared to 19.6 per cent of just dexamethasone

In hospitalised patients taking the ‘Spidex’ cocktail, just 5.4 per cent were admitted to intensive care compared to 19.6 per cent of just dexamethasone

[embedded content]

He found that, in hospitalised patients taking the ‘Spidex’ cocktail, just 5.4 per cent were admitted to intensive care compared to 19.6 per cent of those taking dexamethasone alone.

Now he is calling for wider trials of the Spidex regime as he believes more lives could be saved.

His findings, published in the journal Frontiers in Endocrinology, revealed 40 Covid patients taking Spidex performed better on every clinical, biochemical and radiological measure than 40 patients on a high dose of dexamethasone.

The treatment works by ‘turning off’ the impact the virus has on the body, rather than targeting the virus itself.

Sir Christopher hopes the combination should also work against the mutated Omicron virus.

Leave a Reply

LIVE OFFLINE
track image
Loading...